What is the clinical evidence from this study?

Study design: Cohort. Population: Colorectal cancer (n=215). Intervention: GPD1L. Primary outcome: Overall survival (OS) and recurrence-free survival (RFS) (HR 0.602, 95% CI 0.420–0.865, p=0.005).

What question did this study set out to answer?

This study aims to identify GPD1L as a prognostic biomarker associated with colorectal cancer progression.

January 10, 2026Discover Oncology0 citationsOpen Access

Identification of GPD1L as a potential prognosis biomarker and associated with colorectal cancer progression

YLYa-Rui LiuHuazhong University of Science and Technology YZYing ZengKobe Gakuin University CMChao MeiUnion Hospital

Key Result

GPD1L expression levels are significantly associated with improved overall survival and recurrence-free survival in colorectal cancer patients.

Key Points

This study aims to identify GPD1L as a prognostic biomarker associated with colorectal cancer progression.
Screened genes using The Cancer Genome Atlas and Gene Expression Omnibus databases
Validated results with clinical colorectal cancer samples
Analyzed correlation of clinical characteristics with candidate genes
Evaluated role of candidate genes in cell proliferation, migration, and invasion
GPD1L was identified as a potential biomarker for colorectal cancer prognosis
Significant correlation found between GPD1L expression and clinical outcomes
GPD1L influences cell proliferation, migration, and invasion capabilities in colorectal cancer cells

Study Design

Type

Cohort (n=215)

Multicenter

Structured PICO

Does GPD1L expression level predict prognosis and regulate cell proliferation, migration, and invasion in colorectal cancer?

Population

215 patients with colorectal cancer (CRC) who underwent primary tumor resection, alongside human colon cancer cell lines (HCT116 and LoVo) and public database cohorts (TCGA, GEO).

Intervention

GPD1L expression levels (observational) and GPD1L knockdown using siRNA (in vitro).

Comparator

Adjacent non-tumor tissues, high GPD1L expression, or non-targeting siRNA.

Outcome

Overall survival (OS) and recurrence-free survival (RFS) in CRC patients; cell proliferation, migration, invasion, and cell cycle in vitro.hard clinical

GPD1L is significantly down-regulated in colorectal cancer, and its low expression serves as an independent predictor of poor overall and recurrence-free survival, while its knockdown promotes CRC cell proliferation and invasion in vitro.

Main Result

Effect estimate: HR 0.602 (95% CI 0.420–0.865)

p-value: p=0.005

Limitations

Study conducted at a single center, potentially limiting the generalizability of findings.
Limited sample size might affect the robustness of statistical conclusions.

Abstract

BACKGROUND: Colorectal cancer (CRC) ranks high in both global incidence and mortality rates. The discovery of potential biomarkers and therapeutic targets can effectively improve early diagnosis, treatment efficacy, and prognosis for CRC patients. METHODS: Genes that were abnormally expressed in CRC tumors and associated with patients’ prognosis were first screened in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases; Clinical CRC samples were used to validate the results. The correlation between clinical characteristics and candidate genes, as well as their role in CRC cell proliferation, migration, invasion capability, and the cell cycle were analyzed. RESULTS: The study indicated that glycerol-3-phosphate dehydrogenase 1-like (

Ask AI

Helpful

Bookmark

View Full Paper